Kadimastem Ltd.

📣 Exciting News from Kadimastem and NLS Pharmaceutics AG! We are thrilled to announce the closing of up to $3 million equity financing of preferred shares as part of our strategic partnership with NLS Pharmaceutics. This financing, along with a $25 million equity facility agreement, will help position the merged company to advance innovative therapies in regenerative medicine and address significant unmet medical needs in ALS and diabetes. Specifically, this funding is intended to facilitate the merger by enabling the merged company to execute our phase IIa multi-site clinical trial for Amyotrophic Lateral Sclerosis (ALS) using AstroRx® already approved by the FDA and a phase I for the IseltRx for type 1 diabetes patients, which is planned to commence following the merger Ronen Twito Alex Zwyer https://lnkd.in/dSihrzZU #Kadimastem #Investment #Biotech #ALS #Diabetes

Our Executive Chairman and CEO, Ronen Twito, appeared on Channel 10 this morning to analyze the WIZ sale and its tax implications for both Israeli and foreign investors. He addressed the important tax regulations that impact the Israeli market, particularly for small and medium biotech and high-tech companies and the complexities involved in mergers between Israeli and foreign firms. This segment is essential for understanding the current landscape for investors. 👉 Watch the full segment here: https://lnkd.in/dQmN3n8Q #Kadimastem #Taxation #Biotech #MergersAndAcquisitions #Investment #hightech

Tune in at 11 AM this morning to watch our Executive Chairman and CEO, Ronen Twito, on Israel's most popular economy Channel 10! He'll be discussing taxation and the benefits for Israel following Wiz's impressive $32 billion sale to Google. Ronen may also touch on the opportunities for growth within the #biotech sector, highlighting the importance of supporting small companies that drive #innovation in Israel. Join us for expert commentary on this exciting development and its implications for the Israeli economy! #economy #israel #waze #EconomicInsights #Biotech #Innovation https://tv10.co.il/

Exciting developments in the stem cell therapy market are on the horizon! A recent report from Research and Markets forecasts significant growth, predicting the market will expand from $4.45 billion in 2024 to an impressive $9.95 billion by 2030. This growth is driven by advancements in gene editing, regenerative medicine, and AI-driven therapies, all of which are transforming the landscape of treatments for various medical conditions. At Kadimastem Ltd., we are proud to be at the forefront of this revolution, utilizing our unique allogeneic cell therapy platform to address unmet medical needs in diseases such as Type 1 diabetes and ALS. As we near the upcoming merger deal with NLS Pharmaceutics AG and innovative solutions emerge, our commitment to advancing our transformative treatments for patients remains stronger than ever. Read more about the report here: https://lnkd.in/er-WH3GU Ronen Twito Alex Zwyer #Biotechnology #StemCellTherapy #Innovation #ALS #type1diabetes Source: Research and Markets

Economic Feature on BESHEVA: Ronen Twito in the Spotlight! We're proud to share that our Executive Chairman & CEO, Ronen Twito, was recently featured in an article discussing the challenges faced by small-cap companies on the Tel Aviv Stock Exchange. In the interview, he sheds light on the difficulties these companies encounter in raising capital, managing low trading volumes, and the lack of sufficient analytical support in the biotech sector. Ronen emphasizes the importance of removing regulatory and bureaucratic barriers for foreign investors, as well as the need to enhance interest from institutional investors in the thriving biotech market. His insights offer a roadmap for improving the ecosystem for innovative companies like Kadimastem, ensuring that groundbreaking technologies remain competitive in the global marketplace. We invite you to read the full article to gain deeper insights into the dynamics of the Israeli capital market and the future of biotech: https://lnkd.in/ddabZy4a #Kadimastem #Biotech #Investing #Leadership #IsraelMarket

We're excited to share ACF Equity Research's insights on the transformative potential of regenerative medicine in diabetes treatment. As an organization at the forefront of innovation, Kadimastem Ltd. is dedicated to developing cutting-edge allogeneic cell therapies designed to address the challenges of both Type 1 diabetes. With advancements in stem cell technology, we believe we can pave the way for groundbreaking therapies that offer patients more effective and long-lasting solutions. The future of diabetes care is bright, and we are proud to be part of this revolutionary journey towards improved health outcomes. Ronen Twito #Diabetes #RegenerativeMedicine #StemCellTherapy #Innovation #Healthcare #Biotechnology #T1D #T2D #PatientCare #ClinicalResearch #Biotech #HealthTech #FutureOfMedicine #TransformativeTherapies

📢Kadimastem and NLS Pharmaceutics AG Issues Letter to Shareholders We are thrilled to share a major milestone in our journey toward transformative biotech innovation! With the upcoming merger, we are strengthening our portfolio to address neurodegenerative diseases and Type 1 Diabetes. 🔬 Key Developments: ✔️ Merger, forming NucelX Ltd. (NCEL) ✔️ Nasdaq listing application submitted ✔️ Advancing iTOL-102, a potential Type 1 Diabetes cure ✔️ Post-merger ALS Phase IIa trial launch ✔️ Financial strength: Zero long-term debt & strong cash position Our commitment to patients, innovation, and shareholders remains stronger than ever. Read the full update here: https://lnkd.in/dK2AUG93 #Biotechnology #CNSDisorders #Type1Diabetes #ALS #LifeChangingTherapies #celltherapy #merger #nasdaq Ronen Twito Alex Zwyer

Insightful discussion by Ronen Twito, Executive Chairman and CEO of Kadimastem, joined Israel's Economy Channel (https://tv10.co.il/) to share his perspectives on the #biotech sector in Israel. He highlighted critical issues such as the hurdles faced by publicly traded companies on the Tel Aviv Stock Exchange and the need for improved regulatory support. This conversation sheds light on the investment potential and growth opportunities in #biotechnology. Don't miss this valuable insight! 👉 Watch the full interview here: https://lnkd.in/dRnmSeyd #Biotech #Investment #IsraelEconomy #Leadership

Exciting Financial insights from the world of biotechnology! We would like to share a clip of Ronen Twito, Executive Chairman and CEO of Kadimastem, as he participates in a panel discussion on Israel's Economy Channel (TV10) ערוץ 10 - ערוץ הכלכלה של ישראל . 🎥 In this engaging conversation, Ronen shares his perspectives on the latest trends in the biotech industry and how Kadimastem is positioning itself strategically with its upcoming #Merger with NLS Pharmaceutics AG! Tune in to gain valuable insights on the intersection of mergers and the economy, and discover how Kadimastem is positioning itself to shape the future of healthcare with NLS! 👉 Watch the full segment here: https://lnkd.in/dpjBYKnU #Biotechnology #Kadimastem #Innovation #Healthcare #IsraelEconomy #Leadership

We're Heading to the Premier Health Tech Conference in Israel! Our team is eager to participate in discussions, share insights, and collaborate on innovative solutions. 🤝 Open for Meeting Requests: We welcome the opportunity to connect with fellow attendees, so please feel free to reach out to schedule a meeting! #HealthTech #Innovation #Networking #Conference2025 #IATI Ronen TwitoKfir Molakandov